close

Agreements

1 227 228 229
Number of results: 4569

Excel print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
0000-00-00 Santen Pharmaceutical (Japan) new European Head Quarters in Geneva

opening of new premises

Ophtalmological diseases Opening of new premises
0000-00-00 Bluebird bio (USA - MA)

resignation

Resignation
0000-00-00 Ascendis Pharma (Denmark)

nomination

Nomination
0000-00-00 Macrogenics (USA - MD) Synthon (The Netherlands) MGC018,

licensing

development

Cancer - Oncology - Technology - Services Licensing agreement
0000-00-00 Macrogenics (USA - MD) Synthon (The Netherlands) MGC018,

licensing

development

Cancer - Oncology - Technology - Services Licensing agreement
0000-00-00 Loxo Oncology (USA - CT) Ventana Medical Systems,(USA), a member of the Roche Group (Switzerland) companion diagnostic to identify patients across tumor types suitable for treatment with larotrectinib Cancer - Oncology - Diagnostic Establishment of a new subsidiary in the EU
0000-00-00 OSE Immunotherapeutics (France) Memorial Sloan Kettering Cancer Center (USA - NY) OSE-703 (Effi-3) solid tumors, non-small cell lung cancer (NSCLC) research Cancer - Oncology Research agreement
0000-00-00 Race Oncology (Australia) TargImmune Therapeutics (Switzerland) Race Immunotherapeutics bisantrene combined with TargImmune's targeted cancer therapy technology joint-venture Cancer - Oncology Joint-venture agreement
0000-00-00 vaccine manufacturing site in Val de Reuil influenza construction of new premises Infectious diseases Construction of new premises